1 |
patient-derived xenografts
(492 times)
|
Neoplasms (204 times)
|
CRC (23 times) TNBC (21 times) NSCLC (16 times)
|
2012 Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients.
|
2 |
patient-derived tumor xenografts
(38 times)
|
Neoplasms (19 times)
|
BC (3 times) CRC (2 times) CSCs (2 times)
|
2014 Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings.
|
3 |
patient-derived prostate cancer xenografts
(4 times)
|
Urology (2 times)
|
EBV (1 time) hOTEC (1 time) PEG (1 time)
|
2015 Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice.
|
4 |
panel of sarcoma cell lines and sarcoma tumor xenografts
(1 time)
|
Neoplasms (1 time)
|
---
|
2015 Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.
|
5 |
patient derived ovarian xenografts
(1 time)
|
Neoplasms (1 time)
|
BEV (1 time) MEK (1 time) PTX (1 time)
|
2017 Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
|
6 |
patient tumor tissue derived xenografts
(1 time)
|
Medicine (1 time)
|
GEMMs (1 time)
|
2016 Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.
|
7 |
patient-derived IDH1/2-mutant AML/ MDS xeno-grafts
(1 time)
|
Hematology (1 time)
|
AML (1 time) HR (1 time) MDS (1 time)
|
2022 In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
|
8 |
Patient-derived organoids and xenografts
(1 time)
|
Neoplasms (1 time)
|
---
|
2018 Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response.
|
9 |
patient-derived orthotopic xenografts
(1 time)
|
Neoplasms (1 time)
|
---
|
2016 Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.
|
10 |
patient-derived primary tumour xenografts
(1 time)
|
Neoplasms (1 time)
|
CSCs (1 time)
|
2017 Metformin targets gastric cancer stem cells.
|
11 |
patient-derived xenolines
(1 time)
|
Biochemistry (1 time)
|
GBMs (1 time) GSCs (1 time) IFNs (1 time)
|
2017 The effects of type I interferon on glioblastoma cancer stem cells.
|
12 |
plain decellularized xenografts
(1 time)
|
Transplantation (1 time)
|
---
|
2006 In vivo recellularization of plain decellularized xenografts with specific cell characterization in the systemic circulation: histological and immunohistochemical study.
|